Evidence map›Paper›PMID 41460404›Full record

ArticleEJNMMI radiopharmacy and chemistry2025

Developing a theranostic nanobody targeting FAP for cancer imaging and therapy.

Lital Ben-Naim, Suma Prabhu, Miguel Ferreira, Shvan J Raheem, Shadi A Esfahani, Umar Mahmood, Pedram Heidari

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI radiopharmacy and chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lital Ben-NaimDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit St, White 427J, Boston, MA, 02114, USA.
Suma PrabhuDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit St, White 427J, Boston, MA, 02114, USA.
Miguel FerreiraDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit St, White 427J, Boston, MA, 02114, USA.
Shvan J RaheemDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit St, White 427J, Boston, MA, 02114, USA.
Shadi A EsfahaniDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit St, White 427J, Boston, MA, 02114, USA.
Umar MahmoodDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit St, White 427J, Boston, MA, 02114, USA.
Pedram HeidariDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit St, White 427J, Boston, MA, 02114, USA. heidari.pedram@mgh.harvard.edu.ORCID http://orcid.org/0000-0001-6383-465X

Funding

Postgraduate Training Program in Medical Imaging (PTPMI)T32EB013180 · NIBIB · MASSACHUSETTS GENERAL HOSPITAL · PI Ciprian Catana, Pedram Heidari · 2011 to 2026
$3.7M
Enhancing the therapeutic effect of receptor radionuclide therapy in neuroendocrine tumors by somatostatin receptor upregulationK08CA249047 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI HEIDARI, PEDRAM · 2020 to 2024
$1.3M
Molecular Imaging of Fibrosis for Improved Treatment Planning of Pancreatic Ductal AdenocarcinomaK08CA259626 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Shadi Abdar Esfahani · 2022 to 2026
$1.3M
NCI NIH HHS K08 CA249047NCI NIH HHS K08CA249047NCI NIH HHS K08 CA259626NIBIB NIH HHS T32 EB013180
6 · The paper itself

Abstract

backgroundFibroblast activation protein (FAP) is a pan-cancer target. Its selective expression on the majority of solid tumors with minimal to absent expression in healthy tissues positions FAP as a promising target for radiotheranostic applications. Nanobodies (Nbs) have unique characteristics, including small size, high affinity, stability, and ease of modification, making them ideal candidates for cancer diagnostics and targeted radiotherapeutics. Llama-derived Nbs were generated and screened against full-length FAP, with three unique candidates selected from the library for further characterization. The lead candidate Nb159 was engineered for site-specific radiolabeling with

resultsNb159 exhibited exceptional picomolar binding affinity to FAP with stable interaction and slow dissociation. PET imaging with [

conclusionsThe lead candidate Nb159 holds promise as a versatile platform for FAP-targeted radiotheranostics, with [

Indexed as

Fibroblast activation protein (FAP)Nanobody (Nb)PET imagingRadiotheranosticsTargeted radiotherapy

Identifiers

PMID41460404
PMCPMC12748472

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.